JMP Securities Reiterates Market Outperform on Mirati Therapeutics, Maintains $61 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Mirati Therapeutics (NASDAQ:MRTX) and maintained a $61 price target.
June 16, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Silvan Tuerkcan reiterates a Market Outperform rating on Mirati Therapeutics and maintains a $61 price target.
The news of JMP Securities reiterating a Market Outperform rating and maintaining a $61 price target on Mirati Therapeutics is positive for the company's stock. This reaffirms the analyst's confidence in the company's performance and potential growth, which could lead to an increase in investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100